Effects of Fenofibrate and Bezafibrate on Hyperlipidemia in Rats with Doxorubicin-induced Rat Nephrotic Syndrome

The present study examines the level of secondary hyperlipidemia in a useful model of doxorubicin (DOR) -induced nephrotic rats, and the hypolipidemic effects of fenofibrate (FF) and bezafbrate (BF) on this model. A single intravenous administration of DOR at 5 mg / kg showed mild nephrotic symptoms, and a slight increase in serum lipid levels. DOR at the dose levels of 7.5 and 10 mg / kg caused severe nephrotic syndrome and hyperlipidemia. However, rats with DOR at 10 mg / kg showed distinct differences in the degree of nephrotic and hyperlipidemic levels, and the abnormal behavioral profiles observed, such as piloerection, emaciation and hyperirritability. Therefore, rats administered 7.5 mg/kg of DOR seemed to be a useful model for evaluating the efficacy of hypolipidemic drugs. FF and BF inhibited increases in TC, TG, LDL, VLDL, and chylomicron induced by the administration of DOR at 7.5 mg/kg. The low dose of FF and BF especially inhibited secondary hyperlipidemia caused by the nephrotic syndrome without the exacerbation of nephrotic symptoms. These results suggest that FF and BF may also inhibit secondary hyperlipidemia induced by other diseases such as diabetes, cholestasis and hypothyroidism.